SMLEREVISE

Systemic Lupus Erythematosus

Medically Reviewed by Dr. M. Salar Raza | Official SCFHS 2026 Blueprint

Clinical Pathway

Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease characterized by widespread inflammation and tissue damage, as the immune system mistakenly attacks its own healthy tissues and organs. It can affect nearly any part of the body, including joints, skin, kidneys, brain, heart, and lungs. Treatment for SLE aims to control symptoms, reduce inflammation, prevent organ damage, and minimize flare-ups. This typically involves corticosteroids for acute flares, antimalarials (e.g., hydroxychloroquine) for long-term disease control, and immunosuppressants (e.g., methotrexate, azathioprine, mycophenolate mofetil) for moderate to severe disease. Biologic agents (e.g., belimumab, anifrolumab) are also used for targeted immunomodulation. SLE presents with a diverse range of symptoms due to multi-organ involvement. Common manifestations include joint pain and swelling (arthritis/arthralgia), a characteristic butterfly-shaped malar rash, photosensitivity, oral ulcers, and profound fatigue. More severe features can include lupus nephritis (kidney inflammation), neurological issues (seizures, psychosis), serositis (inflammation of lining of lungs or heart), and hematologic abnormalities (anemia, leukopenia, thrombocytopenia).

Clinical Reasoning

SLE involves a complex interplay of genetic predisposition and environmental triggers, leading to a breakdown of immune tolerance. This results in the production of autoantibodies, particularly antinuclear antibodies (ANAs), which form immune complexes that deposit in various tissues. These immune complexes activate the complement system and trigger inflammatory responses, causing widespread tissue damage and organ dysfunction. The prognosis for SLE has significantly improved over recent decades with advances in diagnosis and treatment. While it is a chronic, lifelong condition with periods of remission and flares, most individuals can achieve good disease control and lead productive lives. The long-term prognosis is highly dependent on the extent of organ involvement, especially the severity of lupus nephritis, requiring close monitoring and adherence to treatment regimens. Female sex (9:1 female-to-male ratio),Age (typically 15-45 years at diagnosis),Family history of SLE or other autoimmune diseases,Ethnicity (higher prevalence in African Americans, Hispanics, Asians),Genetic factors (e.g., HLA genes, complement deficiencies),Environmental triggers (e.g., UV light exposure, certain medications, infections)

Sample MCQ

A 30-year-old woman with systemic lupus erythematosus presents with 3 months of migratory arthralgia, active arthritis in the right 2nd and 3rd MCP joints, and a malar rash. She has a 10-pack-year smoking history, currently smoking 0.5 packs daily. Labs are shown below: | Lab Value | Patient Value | Reference Range | | :------------------------------ | :------------- | :-------------------------- | | Hemoglobin | 110 g/L | 120-160 g/L (Female) | | Platelet count | 190 x 10^9/L | 150-400 x 10^9/L | | White blood cell count | 6 x 10^9/L | 4.5-10.5 x 10^9/L | | Erythrocyte sedimentation rate (ESR) | 35 mm/h | 3-15 mm/h (Female) | Hydroxychloroquine is initiated. What counseling is required?

  • AMay interfere with mycophenolate mofetil activity.
  • BRequires discontinuation during pregnancy.
  • CRequires discontinuation during lactation.
  • DSmoking reduces its therapeutic efficacy.

Correct Answer: D

### TLDR Hydroxychloroquine is a cornerstone therapy for systemic lupus erythematosus, but its efficacy can be significantly hampered by smoking due to increased drug metabolism. Counseling patients about the negative impact of smoking on treatment response is a critical part of disease management. ### Comparison Table | Option | Mechanism | Clinical Nuance | Key Distinction | | :---------------------------------- | :---------------------------- | :------------------------------ | :-------------------------- | | May interfere with mycopphenolate mofetil activity. | No significant pharmacokinetic interaction. | Often co-prescribed safely. | No documented drug-drug inhibition. | | Requires discontinuation during pregnancy. | Considered safe, crosses placenta minimally. | Recommended to continue for flare prevention. | Safe, prevents adverse pregnancy outcomes. | | Requires discontinuation during lactation. | Minimal drug transfer to breast milk. | Compatible; benefits mother, minimal infant risk. | Safe for infant, compatible with breastfeeding. | | **Smoking reduces its therapeutic efficacy.** | Increases drug metabolism, lowers plasma levels. | Associated with worse disease activity. | Reduces bioavailability and clinical response. | ### Detailed Breakdown The question asks for a crucial counseling point regarding hydroxychloroquine for a patient with systemic lupus erythematosus (SLE) and a history of smoking. **Smoking reduces its therapeutic efficacy** is the correct counseling point. Smoking has been consistently linked to reduced therapeutic response to hydroxychloroquine in patients with SLE. The exact mechanisms are multifaceted but are thought to involve increased metabolism of the drug by hepatic enzymes, leading to lower plasma concentrations and reduced bioavailability. Additionally, smoking is independently associated with increased disease activity and organ damage in SLE, further complicating management. Counseling patients to cease or reduce smoking is therefore vital for optimizing treatment outcomes with hydroxychloroquine and for overall SLE management. Let's examine why the other options are incorrect: * **May interfere with mycophenolate mofetil activity.** There is no significant known pharmacokinetic or pharmacodynamic interaction between hydroxychloroquine and mycophenolate mofetil. Both drugs are commonly used in combination for SLE, particularly in cases involving renal or other organ manifestations, without requiring dose adjustments due to interaction. * **Requires discontinuation during pregnancy.** Hydroxychloroquine is considered safe and is generally recommended to be continued throughout pregnancy in women with SLE. It helps prevent disease flares, which can negatively impact maternal and fetal outcomes. Discontinuation is associated with an increased risk of disease activity during pregnancy. * **Requires discontinuation during lactation.** Hydroxychloroquine is considered compatible with breastfeeding. Only minimal amounts of the drug are excreted into breast milk, and no adverse effects have been reported in breastfed infants. Continuing hydroxychloroquine during lactation is beneficial for the mother's disease control without significant risk to the infant.

Master the 2026 SMLE

Explore more clinical protocols in the SMLEREVISE Clinical Knowledge Library.

Try the QBank & Scaled Mocks